Objective To systematically assess the effect of CYP450 inhibitors on the pharmacokinetics and safety of VORI.Methods: Cochrane Library, PubMed, Embase, CNKI, CBM and WanFang databases were searched up to January 26th 2016.Meta analyses were performed with RevMan5.3, and risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs) were calculated.Results: Seventeen studies were included: 1 parallel RCT, 5 cross-over RCTs, 4 single-arm before-and-after studies, 6 cohort studies and 1 case report.Compared with no-combined group, the group of VORI plus omeprazole had a significantly higher occurrence of hepatic dysfunction (RR =4.11, 95% CI 1.12-15.08, P =0.03);however,no difference of neurologic dysfunction was found between VORI plus omeprazole and control group (RR =5,20, 95% CI 0.52-52.47, P =0.16).Similarly for the Cminof VORI, there was no difference between combined and no-combined omeprazole groups (MD =0.18, 95% CI 0.00-0.36, P=0.05).Pantoprazole, rabeprazole, cimetidine, erythromycin and contraceptive significantly increased the peak concentration and concentration-time curve (AUC) of VORI;however, indinavir and etravirine had no significant effect.The variation of pharmacokinetic parameters of VORI co-administeredwith esomeprazole,azithromycin and ritonavir indicated conflict effects.Conclusions: Co-administration of VORI and CYP450 inhibitors was safe except omeprazole.Although the Cmax and AUC of VORI were increased while co-administrated with CYP450 inhibitors,no significantly effect on clinical practice was observed.